bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Data 4 from Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma
Authors: Barwick Benjamin G. , Gupta Vikas A. , Matulis Shannon M. , Patton Jonathan C. , Powell Doris R. , Gu Yanyan , Jaye David L. , Conneely Karen N. , Lin Yin C. , Hofmeister Craig C. , Nooka Ajay K. , Keats Jonathan J. , Lonial Sagar , Vertino Paula M. , Boise Lawrence H.
Published: April 2023

Correlation of regulatory element transcription and gene expression in CoMMpass specimens.
Supplementary Data 2 from Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma
Authors: Barwick Benjamin G. , Gupta Vikas A. , Matulis Shannon M. , Patton Jonathan C. , Powell Doris R. , Gu Yanyan , Jaye David L. , Conneely Karen N. , Lin Yin C. , Hofmeister Craig C. , Nooka Ajay K. , Keats Jonathan J. , Lonial Sagar , Vertino Paula M. , Boise Lawrence H.
Published: April 2023

Regulatory element transcription in newly diagnosed myelomas from CoMMpass.
Supplementary Data from Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer
Authors: Nakajima Takako Eguchi , Kadowaki Shigenori , Minashi Keiko , Nishina Tomohiro , Yamanaka Takeharu , Hayashi Yuichiro , Izawa Naoki , Muro Kei , Hironaka Shuichi , Kajiwara Takeshi , Kawakami Yutaka
Published: April 2023

Table S1, Table S2, Figure S1 (A)(B)(C)(D)and Figure S2(A)(B)
Appendix 2 from Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Authors: Sheng Xinan , Yan Xieqiao , Wang Lin , Shi Yanxia , Yao Xin , Luo Hong , Shi Benkang , Liu Jiyan , He Zhisong , Yu Guohua , Ying Jianming , Han Weiqing , Hu Changlu , Ling Yun , Chi Zhihong , Cui Chuanliang , Si Lu , Fang Jianmin , Zhou Aiping , Guo Jun
Published: April 2023

Flowchart
Table S1 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
Authors: Ferrara Roberto , Naigeon Marie , Auclin Edouard , Duchemann Boris , Cassard Lydie , Jouniaux Jean-Mehdi , Boselli Lisa , Grivel Jonathan , Desnoyer Aude , Mezquita Laura , Texier Matthieu , Caramella Caroline , Hendriks Lizza , Planchard David , Remon Jordi , Sangaletti Sabina , Proto Claudia , Garassino Marina C. , Soria Jean-Charles , Marabelle Aurelien , Voisin Anne-Laure , Farhane Siham , Besse Benjamin , Chaput Nathalie
Published: April 2023

Flow cytometry antibodies and fluorochromes of "T-cell immunosenescence", "Activation and Treg" and "Polarization" panels
Supplementary Figures from Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E Stains
Authors: Klein Sebastian , Quaas Alexander , Quantius Jennifer , Löser Heike , Meinel Jörn , Peifer Martin , Wagner Steffen , Gattenlöhner Stefan , Wittekindt Claus , von Knebel Doeberitz Magnus , Prigge Elena-Sophie , Langer Christine , Noh Ka-Won , Maltseva Margaret , Reinhardt Hans Christian , Büttner Reinhard , Klussmann Jens Peter , Wuerdemann Nora
Published: April 2023

Figure S1, Figure S2
Supplementary Data from Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Authors: Johnson Douglas B. , Zhao Fengmin , Noel Marcus , Riely Gregory J. , Mitchell Edith P. , Wright John J. , Chen Helen X. , Gray Robert J. , Li Shuli , McShane Lisa M. , Rubinstein Larry V. , Patton David , Williams P. Mickey , Hamilton Stanly R. , Conley Barbara A. , Arteaga Carlos L. , Harris Lyndsay N. , O'Dwyer Peter J. , Chen Alice P. , Flaherty Keith T.
Published: April 2023

Supplementary Figure 2: "Swimmer's plot as in Figure 2B also demonstrating mutation locations in individual patients, showing treatment duration for all 32 evaluable patients and their occurrence of response (*), disease progression (+) and death (#)
Supplementary Data from Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Authors: Johnson Douglas B. , Zhao Fengmin , Noel Marcus , Riely Gregory J. , Mitchell Edith P. , Wright John J. , Chen Helen X. , Gray Robert J. , Li Shuli , McShane Lisa M. , Rubinstein Larry V. , Patton David , Williams P. Mickey , Hamilton Stanly R. , Conley Barbara A. , Arteaga Carlos L. , Harris Lyndsay N. , O'Dwyer Peter J. , Chen Alice P. , Flaherty Keith T.
Published: April 2023

Supplementary Figure 8: (A) PFS and (B) OS of patients based on BRAF mutant allele frequency (>= vs. < median).
Supplementary Table 4 from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
Authors: Semaan Alexander , Bernard Vincent , Lee Jaewon J. , Wong Justin W. , Huang Jonathan , Swartzlander Daniel B. , Stephens Bret M. , Monberg Maria E. , Weston Brian R. , Bhutani Manoop S. , Chang Kyle , Scheet Paul A. , Maitra Anirban , Jakubek Yasminka A. , Guerrero Paola A.
Published: April 2023

Comparison of KRAS MAF ddPCR results and KRAS MAF sequencing results, as well as GNAS MAF sequencing results.
Supplementary Table 1 from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
Authors: Semaan Alexander , Bernard Vincent , Lee Jaewon J. , Wong Justin W. , Huang Jonathan , Swartzlander Daniel B. , Stephens Bret M. , Monberg Maria E. , Weston Brian R. , Bhutani Manoop S. , Chang Kyle , Scheet Paul A. , Maitra Anirban , Jakubek Yasminka A. , Guerrero Paola A.
Published: April 2023

Patient cohort and clinicopathological characteristics
Supplementary Data from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
Authors: Semaan Alexander , Bernard Vincent , Lee Jaewon J. , Wong Justin W. , Huang Jonathan , Swartzlander Daniel B. , Stephens Bret M. , Monberg Maria E. , Weston Brian R. , Bhutani Manoop S. , Chang Kyle , Scheet Paul A. , Maitra Anirban , Jakubek Yasminka A. , Guerrero Paola A.
Published: April 2023

It contains supplementary figures
Supplementary Figure S4 from Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment
Authors: Nguyen Tan-Trieu , Ramsay LeeAnn , Ahanfeshar-Adams Mozhdeh , Lajoie Mathieu , Schadendorf Dirk , Alain Tommy , Watson Ian R.
Published: April 2023

Supp Figure S4. JAK1/2 inhibitor Ruxolitinib increases melanoma sensitivity to VSV-d51
Supplementary Figure S3 from Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment
Authors: Nguyen Tan-Trieu , Ramsay LeeAnn , Ahanfeshar-Adams Mozhdeh , Lajoie Mathieu , Schadendorf Dirk , Alain Tommy , Watson Ian R.
Published: April 2023

Supp Figure S3. Effectiveness of OVs does not appear to be dependent on viral genome type
Figure S4 from Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma
Authors: Iorgulescu J. Bryan , Gokhale Prafulla C. , Speranza Maria C. , Eschle Benjamin K. , Poitras Michael J. , Wilkens Margaret K. , Soroko Kara M. , Chhoeu Chhayheng , Knott Aine , Gao Yan , Lim-Fat Mary Jane , Baker Gregory J. , Bonal Dennis M. , Nguyen Quang-Dé , Grant Gareth R. L. , Ligon Keith L. , Sorger Peter K. , Chiocca E. Antonio , Anderson Ana C. , Kirschmeier Paul T. , Sharpe Arlene H. , Freeman Gordon J. , Reardon David A.
Published: April 2023

Figure S4
Figure S3 from Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma
Authors: Iorgulescu J. Bryan , Gokhale Prafulla C. , Speranza Maria C. , Eschle Benjamin K. , Poitras Michael J. , Wilkens Margaret K. , Soroko Kara M. , Chhoeu Chhayheng , Knott Aine , Gao Yan , Lim-Fat Mary Jane , Baker Gregory J. , Bonal Dennis M. , Nguyen Quang-Dé , Grant Gareth R. L. , Ligon Keith L. , Sorger Peter K. , Chiocca E. Antonio , Anderson Ana C. , Kirschmeier Paul T. , Sharpe Arlene H. , Freeman Gordon J. , Reardon David A.
Published: April 2023

Figure S3
Figure S2 from Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma
Authors: Iorgulescu J. Bryan , Gokhale Prafulla C. , Speranza Maria C. , Eschle Benjamin K. , Poitras Michael J. , Wilkens Margaret K. , Soroko Kara M. , Chhoeu Chhayheng , Knott Aine , Gao Yan , Lim-Fat Mary Jane , Baker Gregory J. , Bonal Dennis M. , Nguyen Quang-Dé , Grant Gareth R. L. , Ligon Keith L. , Sorger Peter K. , Chiocca E. Antonio , Anderson Ana C. , Kirschmeier Paul T. , Sharpe Arlene H. , Freeman Gordon J. , Reardon David A.
Published: April 2023

Figure S2
Supplementary Tables 1-4 from Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer
Authors: DeLucia Diana C. , Cardillo Thomas M. , Ang Lisa , Labrecque Mark P. , Zhang Ailin , Hopkins James E. , De Sarkar Navonil , Coleman Ilsa , da Costa Rui M. Gil , Corey Eva , True Lawrence D. , Haffner Michael C. , Schweizer Michael T. , Morrissey Colm , Nelson Peter S. , Lee John K.
Published: April 2023

Supplementary Tables
Supplementary Figure 1 from Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair
Authors: Higuchi Fumi , Nagashima Hiroaki , Ning Jianfang , Koerner Mara V.A. , Wakimoto Hiroaki , Cahill Daniel P.
Published: April 2023

PARP inhibitors restore sensitivity to temozolomide in MSH6-inactivated, temozolomide resistant glioblastoma cells
Supplementary Data from Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer
Authors: Väyrynen Sara A. , Zhang Jinming , Yuan Chen , Väyrynen Juha P. , Dias Costa Andressa , Williams Hannah , Morales-Oyarvide Vicente , Lau Mai Chan , Rubinson Douglas A. , Dunne Richard F. , Kozak Margaret M. , Wang Wenjia , Agostini-Vulaj Diana , Drage Michael G. , Brais Lauren , Reilly Emma , Rahma Osama , Clancy Thomas , Wang Jiping , Linehan David C. , Aguirre Andrew J. , Fuchs Charles S. , Coussens Lisa M. , Chang Daniel T. , Koong Albert C. , Hezel Aram F. , Ogino Shuji , Nowak Jonathan A. , Wolpin Brian M.
Published: April 2023

Supplementary Tables S1-S14 and Supplementary Figures S1-S9
Supplementary Data from Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms
Authors: Rampal Raajit K. , Pinzon-Ortiz Maria , Somasundara Amritha Varshini Hanasoge , Durham Benjamin , Koche Richard , Spitzer Barbara , Mowla Shoron , Krishnan Aishwarya , Li Bing , An Wenbin , Derkach Andriy , Devlin Sean , Rong Xianhui , Longmire Tyler , Eisman Shira Esther , Cordner Keith , Whitfield Justin T. , Vanasse Gary , Cao Zhu A. , Levine Ross L.
Published: April 2023

Complete Supplement
Supplementary Tables from NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes
Authors: Singh Anju , Daemen Anneleen , Nickles Dorothee , Jeon Sang-Min , Foreman Oded , Sudini Kuladeep , Gnad Florian , Lajoie Stephane , Gour Naina , Mitzner Wayne , Chatterjee Samit , Choi Eun-Ji , Ravishankar Buvana , Rappaport Amy , Patil Namrata , McCleland Mark , Johnson Leisa , Acquaah-Mensah George , Gabrielson Edward , Biswal Shyam , Hatzivassiliou Georgia
Published: April 2023

Supplementary Tables
Figure S2 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Authors: Gandhi Shipra , Pandey Manu R. , Attwood Kristopher , Ji Wenyan , Witkiewicz Agnieszka K. , Knudsen Erik S. , Allen Cheryl , Tario Joseph D. , Wallace Paul K. , Cedeno Carlos D. , Levis Maria , Stack Suzanne , Funchain Pauline , Drabick Joseph J. , Bucsek Mark J. , Puzanov Igor , Mohammadpour Hemn , Repasky Elizabeth A. , Ernstoff Marc S.
Published: April 2023

Biomarker changes over time. A, Variations in chemokines IP-10, eotaxin and TNF-β in pg/ml. B, Variation in CD8+T-cells, m-MDSC, PMN-MDSC, regulatory T-cells (Tregs) expressed as percentage of total CD45+ cells, ratio of CD8+/ PMN-MDSC. C, Relative changes in peripheral blood cells (PMN-MDSC, CD8+ T-cell, CD8+ T cells/T-reg) and IL-12p70. Dose level 1 is propranolol 10 mg BID, dose level 2 is propranolol 20 mg BID and dose level 3 is propranolol 30 mg BID. Asterix show significant values at different time points compared to baseline in different dose levels.
Figure S1 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Authors: Gandhi Shipra , Pandey Manu R. , Attwood Kristopher , Ji Wenyan , Witkiewicz Agnieszka K. , Knudsen Erik S. , Allen Cheryl , Tario Joseph D. , Wallace Paul K. , Cedeno Carlos D. , Levis Maria , Stack Suzanne , Funchain Pauline , Drabick Joseph J. , Bucsek Mark J. , Puzanov Igor , Mohammadpour Hemn , Repasky Elizabeth A. , Ernstoff Marc S.
Published: April 2023

Perceived Stress scores (PSS). A, Waterfall plot showing best response per immune-modified RECIST as demonstrated by percentage (%) decrease in tumor size in the nine evaluable patients on the study reporting different PSS scores at baseline. B, Change in median PSS scores with subsequent visits for patients treated at 3 different dose levels. X-axis shows clinic visits and Y-axis shows the median PSS score. Dose level 1 is propranolol 10 mg BID, dose level 2 is propranolol 20 mg BID and dose level 3 is propranolol 30 mg BID. The numbers of patients at different time points reporting the PSS scores are shown on the graphs.
Supplementary Figure 2 from A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Authors: Varga Andrea , Soria Jean-Charles , Hollebecque Antoine , LoRusso Patricia , Bendell Johanna , Huang Shih-Min A. , Wagle Marie-Claire , Okrah Kwame , Liu Lichuan , Murray Elaine , Sanabria-Bohorquez Sandra M. , Tagen Michael , Dokainish Hatem , Mueller Lars , Burris Howard
Published: April 2023

Supplemental Figure 2. MAPK pathway signature is specifically inhibited on treatment (A). Differential expression of 11 PROGENy (pathway) scores between pre and post-treatment samples (B). Only MAPK and EGFR scores are statistically significant (rank-sum test).
Figure S2 from TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti–PD-1 Response in Follicular Lymphoma
Authors: Yang Zhi-Zhang , Kim Hyo Jin , Wu Hongyan , Jalali Shahrzad , Tang Xinyi , Krull Jordan E. , Ding Wei , Novak Anne J. , Ansell Stephen M.
Published: April 2023

Th cells gating strategy
Supplementary Data from A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Authors: Varga Andrea , Soria Jean-Charles , Hollebecque Antoine , LoRusso Patricia , Bendell Johanna , Huang Shih-Min A. , Wagle Marie-Claire , Okrah Kwame , Liu Lichuan , Murray Elaine , Sanabria-Bohorquez Sandra M. , Tagen Michael , Dokainish Hatem , Mueller Lars , Burris Howard
Published: April 2023

Word doc with tables
Supplementary Table 2 from A Performance Comparison of Commonly Used Assays to Detect RET Fusions
Authors: Yang Soo-Ryum , Aypar Umut , Rosen Ezra Y. , Mata Douglas A. , Benayed Ryma , Mullaney Kerry , Jayakumaran Gowtham , Zhang Yanming , Frosina Denise , Drilon Alexander , Ladanyi Marc , Jungbluth Achim A. , Rekhtman Natasha , Hechtman Jaclyn F.
Published: April 2023

Supplementary Table 2: Clinicopathologic and molecular characteristics of Group D cases.
Supplementary Figure S1 from A Performance Comparison of Commonly Used Assays to Detect RET Fusions
Authors: Yang Soo-Ryum , Aypar Umut , Rosen Ezra Y. , Mata Douglas A. , Benayed Ryma , Mullaney Kerry , Jayakumaran Gowtham , Zhang Yanming , Frosina Denise , Drilon Alexander , Ladanyi Marc , Jungbluth Achim A. , Rekhtman Natasha , Hechtman Jaclyn F.
Published: April 2023

Supplementary Figure 1: (A) RET SVUS that did not express RET fusion transcripts on RNA sequencing (group D cases). (B) Location of KIF5B (NM_004521), RET (NM_020975), NCOA4 (NM_001145260), and CCDC6 (NM_005436) in relation to the break-apart FISH probes on chromosome 10. Red (5') and green (3') probes for FISH are provided. The distance between KIF5B and RET is approximately 11.2 Mb, whereas the distance between NCOA4 and RET is approximately 7.9 Mb.
Supplemental Figure 4 from Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses
Authors: Aggen David H. , Ager Casey R. , Obradovic Aleksandar Z. , Chowdhury Nivedita , Ghasemzadeh Ali , Mao Wendy , Chaimowitz Matthew G. , Lopez-Bujanda Zoila A. , Spina Catherine S. , Hawley Jessica E. , Dallos Matthew C. , Zhang Cheng , Wang Vinson , Li Hu , Guo Xinzheng V. , Drake Charles G.
Published: April 2023

Single-cell analysis clustering for gene profiling.
Supplemental Figure 1 from Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses
Authors: Aggen David H. , Ager Casey R. , Obradovic Aleksandar Z. , Chowdhury Nivedita , Ghasemzadeh Ali , Mao Wendy , Chaimowitz Matthew G. , Lopez-Bujanda Zoila A. , Spina Catherine S. , Hawley Jessica E. , Dallos Matthew C. , Zhang Cheng , Wang Vinson , Li Hu , Guo Xinzheng V. , Drake Charles G.
Published: April 2023

Transcript level assessment of angiogenic signatures in CD45+ intratumoral cells with anti-IL-1b and cabozantinib
Supplementary Table 2 from Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA
Authors: Gao ChongFeng , Wisniewski Luke , Liu Ying , Staal Ben , Beddows Ian , Plenker Dennis , Aldakkak Mohammed , Hall Johnathan , Barnett Daniel , Gouda Mirna Kheir , Allen Peter , Drake Richard , Zureikat Amer , Huang Ying , Evans Douglas , Singhi Aatur , Brand Randall E. , Tuveson David A. , Tsai Susan , Haab Brian B.
Published: April 2023

Tissue-microarray analyses
Supplemental Data from Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA
Authors: Gao ChongFeng , Wisniewski Luke , Liu Ying , Staal Ben , Beddows Ian , Plenker Dennis , Aldakkak Mohammed , Hall Johnathan , Barnett Daniel , Gouda Mirna Kheir , Allen Peter , Drake Richard , Zureikat Amer , Huang Ying , Evans Douglas , Singhi Aatur , Brand Randall E. , Tuveson David A. , Tsai Susan , Haab Brian B.
Published: April 2023

Supplemental Table 4 Supplemental Figures 1-8 Supplemental Methods
Figure S13 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Authors: Lin Xiaojing , Qiao Niu , Shen Yang , Fang Hai , Xue Qing , Cui Bowen , Chen Li , Zhu Hongming , Zhang Sujiang , Chen Yu , Jiang Lu , Wang Shengyue , Li Junmin , Wang Bingshun , Chen Bing , Chen Zhu , Chen Saijuan
Published: April 2023

Figure S13. Establishment of a revised risk model for three groups. (A) The chart is presented to show the score of the revised risk model in three groups. In each cell of the chart, the risk for a person is estimated using the values of each predictor according to the multivariate Cox model. Then, the cells of the chart are colored in three groups in accordance with the ranges of the risk status: 0-1, 2, and 3-5. (B) Sankey plot for reclassification from the Sanz risk to the revised risk model. (C) Kaplan-Meier estimates of OS, EFS, and DFS in accordance with the revised risk groups of the entire cohort. (D) Kaplan-Meier estimates of OS, EFS, and DFS in accordance with the Sanz risk stratification. P-value is calculated using the log-rank test. HR, high-risk; MR, intermediate-risk; SR, standard-risk; OS, overall survival; EFS, event-free survival; DFS, disease-free survival.
Figure S10 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Authors: Lin Xiaojing , Qiao Niu , Shen Yang , Fang Hai , Xue Qing , Cui Bowen , Chen Li , Zhu Hongming , Zhang Sujiang , Chen Yu , Jiang Lu , Wang Shengyue , Li Junmin , Wang Bingshun , Chen Bing , Chen Zhu , Chen Saijuan
Published: April 2023

Figure S10. The outcomes of different APL9 score groups. (A) Sankey plot for reclassification from the Sanz risk to the APL9 score groups in the training cohort. (B) Kaplan-Meier estimates of OS, EFS, and DFS in accordance with the APL9 score groups of the training cohort. (C) Sankey plot for reclassification from the Sanz risk to the APL9 score groups in the validation cohort. (D) Kaplan-Meier estimates of OS, EFS, and DFS in accordance with the APL9 score groups of the validation cohort. (E) Area under the curve (AUC) for APL9 score to assess patients' molecular risk status as subcohorts (SC) 1 and 2 in the training (n = 158) and validation (n = 104) cohort. P-value is calculated using the log-rank test. OS, overall survival; EFS, event-free survival; DFS, disease-free survival; CI, confidence interval.
Supplementary Methods from Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers
Authors: Parikh Aparna R. , Mojtahed Amikasra , Schneider Jaime L. , Kanter Katie , Van Seventer Emily E. , Fetter Isobel J. , Thabet Ashraf , Fish Madeleine G. , Teshome Bezaye , Fosbenner Kathryn , Nadres Brandon , Shahzade Heather A. , Allen Jill N. , Blaszkowsky Lawrence S. , Ryan David P. , Giantonio Bruce , Goyal Lipika , Nipp Ryan D. , Roeland Eric , Weekes Colin D. , Wo Jennifer Y. , Zhu Andrew X. , Dias-Santagata Dora , Iafrate A. John , Lennerz Jochen K. , Hong Theodore S. , Siravegna Giulia , Horick Nora , Clark Jeffrey W. , Corcoran Ryan B.
Published: April 2023

Supplementary Methods
Supplementary Data from Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers
Authors: Parikh Aparna R. , Mojtahed Amikasra , Schneider Jaime L. , Kanter Katie , Van Seventer Emily E. , Fetter Isobel J. , Thabet Ashraf , Fish Madeleine G. , Teshome Bezaye , Fosbenner Kathryn , Nadres Brandon , Shahzade Heather A. , Allen Jill N. , Blaszkowsky Lawrence S. , Ryan David P. , Giantonio Bruce , Goyal Lipika , Nipp Ryan D. , Roeland Eric , Weekes Colin D. , Wo Jennifer Y. , Zhu Andrew X. , Dias-Santagata Dora , Iafrate A. John , Lennerz Jochen K. , Hong Theodore S. , Siravegna Giulia , Horick Nora , Clark Jeffrey W. , Corcoran Ryan B.
Published: April 2023

Supplementary Figures
Supplementary Materials & Methods from Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy
Authors: Chen Jingwei , Nelson Christopher , Wong Matthew , Tee Andrew E. , Liu Pei Y. , La Ting , Fletcher Jamie I. , Kamili Alvin , Mayoh Chelsea , Bartenhagen Christoph , Trahair Toby N. , Xu Ning , Jayatilleke Nisitha , Wong Marie , Peng Hui , Atmadibrata Bernard , Cheung Belamy B. , Lan Qing , Bryan Tracy M. , Mestdagh Pieter , Vandesompele Jo , Combaret Valerie , Boeva Valentina , Wang Jenny Y. , Janoueix-Lerosey Isabelle , Cowley Mark J. , MacKenzie Karen L. , Dolnikov Alla , Li Jinyan , Polly Patsie , Marshall Glenn M. , Reddel Roger R. , Norris Murray D. , Haber Michelle , Fischer Matthias , Zhang Xu D. , Pickett Hilda A. , Liu Tao
Published: April 2023

Re - Revised Supplementary Materials & Methods
Supplementary Figure S8 from Agrin in the Muscularis Mucosa Serves as a Biomarker Distinguishing Hyperplastic Polyps from Sessile Serrated Lesions
Authors: Rickelt Steffen , Condon Charlene , Mana Miyeko , Whittaker Charlie , Pfirschke Christina , Roper Jatin , Patil Deepa T. , Brown Ian , Mattia Anthony R. , Zukerberg Lawrence , Zhao Qing , Chetty Runjan , Lauwers Gregory Y. , Neyaz Azfar , Leijssen Lieve G.J. , Boylan Katherine , Yilmaz Omer H. , Deshpande Vikram , Hynes Richard O.
Published: April 2023

AGRN muscularis mucosae reactivity could assist in differentiating tubular adenomas from incomplete fragments of SSL with dysplasia.
Supplementary Figure S7 from Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy
Authors: Chen Jingwei , Nelson Christopher , Wong Matthew , Tee Andrew E. , Liu Pei Y. , La Ting , Fletcher Jamie I. , Kamili Alvin , Mayoh Chelsea , Bartenhagen Christoph , Trahair Toby N. , Xu Ning , Jayatilleke Nisitha , Wong Marie , Peng Hui , Atmadibrata Bernard , Cheung Belamy B. , Lan Qing , Bryan Tracy M. , Mestdagh Pieter , Vandesompele Jo , Combaret Valerie , Boeva Valentina , Wang Jenny Y. , Janoueix-Lerosey Isabelle , Cowley Mark J. , MacKenzie Karen L. , Dolnikov Alla , Li Jinyan , Polly Patsie , Marshall Glenn M. , Reddel Roger R. , Norris Murray D. , Haber Michelle , Fischer Matthias , Zhang Xu D. , Pickett Hilda A. , Liu Tao
Published: April 2023

Supplementary Figure S7. OTX015 and carfilzomib synergistically improve mouse survival in a PDX model of TERT-rearranged neuroblastoma.
Supplementary Figure S4 from Agrin in the Muscularis Mucosa Serves as a Biomarker Distinguishing Hyperplastic Polyps from Sessile Serrated Lesions
Authors: Rickelt Steffen , Condon Charlene , Mana Miyeko , Whittaker Charlie , Pfirschke Christina , Roper Jatin , Patil Deepa T. , Brown Ian , Mattia Anthony R. , Zukerberg Lawrence , Zhao Qing , Chetty Runjan , Lauwers Gregory Y. , Neyaz Azfar , Leijssen Lieve G.J. , Boylan Katherine , Yilmaz Omer H. , Deshpande Vikram , Hynes Richard O.
Published: April 2023

AGRN basal lamina reactivity in mouse models of colorectal cancer.
Supplementary Figure 6 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
Authors: Thakur Shilpa , Daley Brianna , Millo Corina , Cochran Craig , Jacobson Orit , Lu Huiyan , Wang Zhantong , Kiesewetter Dale , Chen Xiaoyuan , Vasko Vasyl , Klubo-Gwiezdzinska Joanna
Published: April 2023

Supplemental figure 6: Treatment with epigenetic modulators did not increase 86Y-DOTA-EB-TATE uptake within the tumor and normal tissues of the mice models. (A) The bar graph shows quantification of 86Y-DOTA-EB-TATE in the tumor and normal tissues (liver, kidneys, spleen, heart, and lungs) of the control (n=5) and VAC treated (n=5) FTC133 subcutaneous xenograft mice. p=NS (non-significant) w.r.t corresponding control mice tissues; ***p<0.001, **p<0.01 w.r.t control tumor; ^^^p<0.001, ^^p<0.01, ^p<0.05 w.r.t VAC tumor. C-control; VAC- valproic acid. (B) The bar graph shows quantification of 86Y-DOTA-EB-TATE in the tumor and normal tissues (liver, kidneys, spleen, heart, and lungs) of the control (n=4) and VAC treated (n=5) AR42J subcutaneous xenograft mice. p=NS (non-significant) w.r.t corresponding control mice tissues; **p<0.01, *p<0.05 w.r.t control tumor; ^^^p<0.001 w.r.t VAC tumor. C-control; VAC- valproic acid. (C) The bar graph shows quantification of 86Y-DOTA-EB-TATE in the tumor and normal tissues (liver, kidneys, spleen, heart, and lungs) of the control (n=3) and DEC treated (n=3) FTC133 subcutaneous xenograft mice. p=NS (non-significant) w.r.t corresponding control mice tissues; **p<0.01, *p<0.05 w.r.t control tumor; ^^p<0.01, ^p<0.05 w.r.t DEC tumor. C-control; DEC- decitabine. (D) The bar graph shows quantification of 86Y-DOTA-EB-TATE in the tumor and normal tissues (liver, kidneys, spleen, heart, and lungs) of the control (n=5) and DEC treated (n=3) AR42J subcutaneous xenograft mice. p=NS (non-significant) w.r.t corresponding control mice tissues; **p<0.01, *p<0.05 w.r.t control tumor; ^^p<0.01, ^p<0.05 w.r.t DEC tumor. C-control; DEC- decitabine.
Supplementary Figure 2 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
Authors: Thakur Shilpa , Daley Brianna , Millo Corina , Cochran Craig , Jacobson Orit , Lu Huiyan , Wang Zhantong , Kiesewetter Dale , Chen Xiaoyuan , Vasko Vasyl , Klubo-Gwiezdzinska Joanna
Published: April 2023

Supplemental figure 2: Valproic acid is a superior epigenetic modifier in upregulating SSTR2 expression in thyroid cancer cell lines. (A, B) VAC (300 ug/mL, equivalent to 2 mM), TAC (500 ng/mL), and DEC (75 ng/mL) treatment upregulates SSTR2 expression in FTC133 (n=3) and BCPAP (n=3) cells. ***p<0.001; **p<0.01; p<0.05. C- control; VAC- valproic acid; TAC- tacedinaline; DEC- decitabine.
Supplementary Table S5 from Integrative Analysis of miRNAs Identifies Clinically Relevant Epithelial and Stromal Subtypes of Head and Neck Squamous Cell Carcinoma
Authors: Holt Jeremiah , Walter Vonn , Yin Xiaoying , Marron David , Wilkerson Matthew D. , Choi Hyo Young , Zhao Xiaobei , Jo Heejoon , Hayes David Neil , Ko Yoon Ho
Published: April 2023

Cox regression for survival in miRNA-based subtypes and miRNAs individually associated with prognosis and HPV status in the TCGA cohort.
Supplementary Table S4 from Integrative Analysis of miRNAs Identifies Clinically Relevant Epithelial and Stromal Subtypes of Head and Neck Squamous Cell Carcinoma
Authors: Holt Jeremiah , Walter Vonn , Yin Xiaoying , Marron David , Wilkerson Matthew D. , Choi Hyo Young , Zhao Xiaobei , Jo Heejoon , Hayes David Neil , Ko Yoon Ho
Published: April 2023

PAGE enrichment z-scores and q-values.
Supplementary material from Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia
Authors: Rovida Alessandra , Maccalli Cristina , Scarfò Lydia , Dellabona Paolo , Stamatopoulos Kostas , Ghia Paolo
Published: April 2023

Supplementary methods, Supplementary Figure 1, Supplementary Figure 2, Supplementary Figure 3, Supplementary Figure 4, Supplementary Table 1, Supplementary Table 2, Supplementary Table 3, Supplementary Table 4 Supplementary References
Supplementary fig 3 from High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors
Authors: Lin Lin , Kane Nathanael , Kobayashi Naoko , Kono Evelyn A. , Yamashiro Joyce M. , Nickols Nicholas G. , Reiter Robert E.
Published: April 2023

Supplemental 3. Radiation temporarily increases tumor resident MDSC population in MycCap tumors
Supplementary fig 2 from High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors
Authors: Lin Lin , Kane Nathanael , Kobayashi Naoko , Kono Evelyn A. , Yamashiro Joyce M. , Nickols Nicholas G. , Reiter Robert E.
Published: April 2023

Supplemental 2. RT 1x 8Gy induced immediate reduction of CD8 TILs, but did not induce significant CD8 TIL expansion at later time points.
Figure S4 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

KM analyses by HPV+ and cN, DeepPET-OPSCC risk category, entire cohort
Figure S3 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

KM analyses by HPV+ and cT, DeepPET-OPSCC risk category, entire cohort
Table S6 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Authors: Adib Elio , Klonowska Katarzyna , Giannikou Krinio , Do Khanh T. , Pruitt-Thompson Solida , Bhushan Ketki , Milstein Matthew I. , Hedglin Jennifer , Kargus Katherine E. , Sholl Lynette M. , Tsuji Junko , Hyman David M. , Sisk Anne , Shapiro Geoffrey I. , Vargas Hebert A. , Harding James J. , Voss Martin H. , Iyer Gopa , Kwiatkowski David J.
Published: April 2023

Table S6. Copy number alterations (CNAs) in cancer genes identified by whole exome sequencing (WES) and/or initial panel sequencing. Each sheet is a different tumor sample.
Figure S18 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

Time-dependent ROC analyses, 2-year survival, DeepPET-OPSCC score, clinical factors, nomograms, clinical deployment test cohort
Figure S17 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

KM analyses, DeepPET-OPSCC risk category, clinical deployment test cohort
Table S2 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Authors: Adib Elio , Klonowska Katarzyna , Giannikou Krinio , Do Khanh T. , Pruitt-Thompson Solida , Bhushan Ketki , Milstein Matthew I. , Hedglin Jennifer , Kargus Katherine E. , Sholl Lynette M. , Tsuji Junko , Hyman David M. , Sisk Anne , Shapiro Geoffrey I. , Vargas Hebert A. , Harding James J. , Voss Martin H. , Iyer Gopa , Kwiatkowski David J.
Published: April 2023

Table S2. Demographic and clinical characteristics of 30 cancer patients with mTOR pathway mutations. S2.1. Master table showing a summary of demographic characteristics and clinical outcomes. S2.2. Prior systemic treatment regimens. S2.3. Objective response to everolimus according to RECIST v1.1 criteria. S2.4. Toxicity profile of patients according to CTCAE v4.0.
Fig S2 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Authors: Adib Elio , Klonowska Katarzyna , Giannikou Krinio , Do Khanh T. , Pruitt-Thompson Solida , Bhushan Ketki , Milstein Matthew I. , Hedglin Jennifer , Kargus Katherine E. , Sholl Lynette M. , Tsuji Junko , Hyman David M. , Sisk Anne , Shapiro Geoffrey I. , Vargas Hebert A. , Harding James J. , Voss Martin H. , Iyer Gopa , Kwiatkowski David J.
Published: April 2023

Fig S2. Nonsynonymous (left panel) and overall (right panel) tumor mutation burden (TMB) for subjects that achieved clinical benefit and those who had no clinical benefit (NCB). TMB for each patient is SNVs/indels per megabase of targeted capture genomic region. The horizontal bars indicate median values. Note that y axis is log scale. Abbreviations: UTUC - upper tract urothelial carcinoma.
Figures S1 - S6 from Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
Authors: Tsimberidou Apostolia M. , Beer Philip A. , Cartwright Carrie A. , Haymaker Cara , Vo Henry H. , Kiany Simin , Cecil Alexander R.L. , Dow James , Haque Kemal , Silva Franck A. , Coe Lucy , Berryman Helen , Bone Elisabeth A. , Nogueras-Gonzalez Graciela M. , Vining David , McElwaine-Johnn Hilary , Wistuba Ignacio I.
Published: April 2023

Supplementary Figures
Supplementary Tables S1-S3 from The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology
Authors: Schneider Julie A. , Gong Yutao , Goldberg Kirsten B. , Kluetz Paul G. , Theoret Marc R. , Amiri-Kordestani Laleh , Beaver Julia A. , Fashoyin-Aje Lola , Gormley Nicole J. , Jaigirdar Adnan A. , Lemery Steven J. , Mishra-Kalyani Pallavi S. , Reaman Gregory H. , Rivera Donna R. , Rubinstein Wendy S. , Singh Harpreet , Sridhara Rajeshwari , Pazdur Richard
Published: April 2023

Supplementary Tables S1-S3
Supplementary Table 4 from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Authors: Bockorny Bruno , Macarulla Teresa , Semenisty Valerya , Borazanci Erkut , Feliu Jaime , Ponz-Sarvise Mariano , Abad David Gutierrez , Oberstein Paul , Alistar Angela , Muñoz Andres , Geva Ravit , Guillén-Ponce Carmen , Fernandez Mercedes Salgado , Peled Amnon , Chaney Marya , Gliko-Kabir Irit , Shemesh-Darvish Liron , Ickowicz Debby , Sorani Ella , Kadosh Shaul , Vainstein-Haras Abi , Hidalgo Manuel
Published: April 2023

Supplementary Table 4
Figure S2 from Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
Authors: Do Khanh T. , Kochupurakkal Bose , Kelland Sarah , de Jonge Adrienne , Hedglin Jennifer , Powers Allison , Quinn Nicholas , Gannon Courtney , Vuong Loan , Parmar Kalindi , Lazaro Jean-Bernard , D'Andrea Alan D. , Shapiro Geoffrey I.
Published: April 2023

Overall Clinical Response in All Evaluable Patients
Figure S3 from A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Authors: Shafique Michael R. , Fisher Terrence L. , Evans Elizabeth E. , Leonard John E. , Pastore Desa Rae E. , Mallow Crystal L. , Smith Ernest , Mishra Vikas , Schröder Andreas , Chin Kevin M. , Beck Joseph T. , Baumgart Megan A. , Govindan Ramaswamy , Gabrail Nashat Y. , Spira Alexander I. , Seetharamu Nagashree , Lou Yanyan , Mansfield Aaron S. , Sanborn Rachel E. , Goldman Jonathan W. , Zauderer Maurice
Published: April 2023

Change from baseline in target lesion diameters: 3A, Spider plot of the change in the sum of target lesion diameters from baseline over time for evaluable immunotherapy naive patients (n=21). The lines are color coded based on best response; * pretracheal LN measured 8 mm at last scan resulting in a response of CR in the target lesion, but overall response of PR due to presence of non-target lesion. 3B, Spider plot of the change in the sum of target lesion diameters from baseline over time for evaluable immunotherapy failure patients (n=29). The lines are color coded based on best response.
Supplementary Table S1 from A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors
Authors: Chida Keigo , Kawazoe Akihito , Kawazu Masahito , Suzuki Toshihiro , Nakamura Yoshiaki , Nakatsura Tetsuya , Kuwata Takeshi , Ueno Toshihide , Kuboki Yasutoshi , Kotani Daisuke , Kojima Takashi , Taniguchi Hiroya , Mano Hiroyuki , Ikeda Masafumi , Shitara Kohei , Endo Itaru , Yoshino Takayuki
Published: April 2023

Patient characteristics according to TMB status
Supplementary Figure S8 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S8 shows the sample selection process and gating strategy used to obtain viable CD45+ cells from HGSC tumor samples for the single-cell sequencing experiment.
Supplementary Data from Genomic Landscape and Tumor Mutational Burden Determination of Circulating Tumor DNA in Over 5,000 Chinese Patients with Lung Cancer
Authors: Shi Jie , Wang Zhiyu , Zhang Junping , Xu Yaping , Xiao Xiao , Quan Xiangming , Bai Ying , Yang Xia , Ming Zongjuan , Guo Xiaojin , Feng Huijing , Yang Xiaoling , Zhuang Xiaofei , Han Fei , Wang Kai , Shi Yonglei , Lei Yu , Bai Jun , Yang Shuanying
Published: April 2023

Supplementary Figures
Supplementary Figure S3 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S3 shows the distribution of CD39, CD103 and PD1-expressing cells in unmatched PBMC from healthy donors and HGSC tumor samples.
Supplementary Figure S15 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S15 shows the differential gene expression and TCR repertoire analysis across all subsets of Tregs isolated from primary HGSC tumor samples.
Supplementary Figure from Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms
Authors: Abbott Charles W. , Boyle Sean M. , Pyke Rachel Marty , McDaniel Lee D. , Levy Eric , Navarro Fábio C.P. , Mellacheruvu Dattatreya , Zhang Simo V. , Tan Mengyao , Santiago Rose , Rusan Zeid M. , Milani Pamela , Bartha Gabor , Harris Jason , McClory Rena , Snyder Michael P. , Jang Sekwon , Chen Richard
Published: April 2023

Supplementary Figure from Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms
Supplemental Table 1 from Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial
Authors: Jones Robin L. , Wagner Andrew J. , Kawai Akira , Tamura Kazuo , Shahir Ashwin , Van Tine Brian A. , Martín-Broto Javier , Peterson Patrick M. , Wright Jennifer , Tap William D.
Published: April 2023

Cardiac treatment-emergent adverse events in the two trial groups
Supplementary Data from OCaMIR—A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study
Authors: Kandimalla Raju , Wang Wei , Yu Fan , Zhou Nianxin , Gao Feng , Spillman Monique , Moukova Lucie , Slaby Ondrej , Salhia Bodour , Zhou Shengtao , Wang Xin , Goel Ajay
Published: April 2023

Supplementary data
Supplementary Figure Legends and Tables from Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET
Authors: Nagle Veronica L. , Henry Kelly E. , Hertz Charli Ann J. , Graham Maya S. , Campos Carl , Parada Luis F. , Pandit-Taskar Neeta , Schietinger Andrea , Mellinghoff Ingo K. , Lewis Jason S.
Published: April 2023

Supplementary Figure Legends and Tables
Figure S9 from Non-invasive Detection of Immunotherapy-Induced Adverse Events
Authors: Ferreira Carolina A. , Heidari Pedram , Ataeinia Bahar , Sinevici Nicoleta , Sise Meghan E. , Colvin Robert B. , Wehrenberg-Klee Eric , Mahmood Umar
Published: April 2023

Supplementary Figure S9
Supplementary Figure 3 from Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer
Authors: Guardia Cristina , Bianchini Giampaolo , Arpí-LLucià Oriol , Menendez Silvia , Casadevall David , Galbardi Barbara , Dugo Matteo , Servitja Sonia , Montero Juan Carlos , Soria-Jiménez Luis , Sabbaghi MohammadA , Peña Raul , Madoz-Gúrpide Juan , Lloveras Belen , Lluch Ana , Eroles Pilar , Arribas Joaquin , Pandiella Atanasio , Gianni Luca , Rojo Federico , Rovira Ana , Albanell Joan
Published: April 2023

Supplementary Figure 3 shows how trastuzumab plus pertuzumab, but not trastuzumab alone, overcome NRG1 enhanced pro-survival signaling in HER2-positive breast cancer cells and in ex vivo tumors.
Figure S4 from Non-invasive Detection of Immunotherapy-Induced Adverse Events
Authors: Ferreira Carolina A. , Heidari Pedram , Ataeinia Bahar , Sinevici Nicoleta , Sise Meghan E. , Colvin Robert B. , Wehrenberg-Klee Eric , Mahmood Umar
Published: April 2023

Supplementary Figure S4
Supplementary Appendix from Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
Authors: Morris Michael J. , Rowe Steven P. , Gorin Michael A. , Saperstein Lawrence , Pouliot Frédéric , Josephson David , Wong Jeffrey Y.C. , Pantel Austin R. , Cho Steve Y. , Gage Kenneth L. , Piert Morand , Iagaru Andrei , Pollard Janet H. , Wong Vivien , Jensen Jessica , Lin Tess , Stambler Nancy , Carroll Peter R. , Siegel Barry A.
Published: April 2023

CONDOR study group, Supplementary tables, Study Protocol, & Medical Management Questionnaires
Supplementary Figure S3 from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions
Authors: Odintsov Igor , Lui Allan J.W. , Sisso Whitney J. , Gladstone Eric , Liu Zebing , Delasos Lukas , Kurth Renate I. , Sisso Exequiel M. , Vojnic Morana , Khodos Inna , Mattar Marissa S. , de Stanchina Elisa , Leland Shawn M. , Ladanyi Marc , Somwar Romel
Published: April 2023

Supplementary Figure S3 shows the doubling time of cells that were treated with seribantumab or afatinib.
Figure S1 from Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
Authors: Morris Michael J. , Rowe Steven P. , Gorin Michael A. , Saperstein Lawrence , Pouliot Frédéric , Josephson David , Wong Jeffrey Y.C. , Pantel Austin R. , Cho Steve Y. , Gage Kenneth L. , Piert Morand , Iagaru Andrei , Pollard Janet H. , Wong Vivien , Jensen Jessica , Lin Tess , Stambler Nancy , Carroll Peter R. , Siegel Barry A.
Published: April 2023

Negative or Equivocal Baseline Imaging
Supplementary Figure S1 from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions
Authors: Odintsov Igor , Lui Allan J.W. , Sisso Whitney J. , Gladstone Eric , Liu Zebing , Delasos Lukas , Kurth Renate I. , Sisso Exequiel M. , Vojnic Morana , Khodos Inna , Mattar Marissa S. , de Stanchina Elisa , Leland Shawn M. , Ladanyi Marc , Somwar Romel
Published: April 2023

Supplementary Figure S1 shows the level of expression of NRG1 alpha and beta isoform mRNA in patient-derived cell lines with NRG1 alterations
Figure S3 from Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer
Authors: Marshall Catherine H. , Fu Wei , Wang Hao , Park Jong Chul , DeWeese Theodore L. , Tran Phuoc T. , Song Daniel Y. , King Serina , Afful Michaella , Hurrelbrink Julia , Manogue Charlotte , Cotogno Patrick , Moldawer Nancy P. , Barata Pedro C. , Drake Charles G. , Posadas Edwin M. , Armstrong Andrew J. , Sartor Oliver , Antonarakis Emmanuel S.
Published: April 2023

Figure S3
Supplementary Figure S4 from PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
Authors: Veach Darren R. , Storey Claire M. , Lückerath Katharina , Braun Katharina , von Bodman Christian , Lamminmäki Urpo , Kalidindi Teja , Strand Sven-Erik , Strand Joanna , Altai Mohamed , Damoiseaux Robert , Zanzonico Pat , Benabdallah Nadia , Pankov Dmitry , Scher Howard I. , Scardino Peter , Larson Steven M. , Lilja Hans , McDevitt Michael R. , Thorek Daniel L.J. , Ulmert David
Published: April 2023

Supplementary Figure S4. Male cynomolgus macaque were intravenously administered 115{plus minus}1MBq (3.1{plus minus}0.3mCi) of [89Zr]hu5A10 at 0.2 mg/kg for longitudinal immune-PET imaging.
Table S4 from An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer
Authors: Bai Yalai , Cole Kimberly , Martinez-Morilla Sandra , Ahmed Fahad Shabbir , Zugazagoitia Jon , Staaf Johan , Bosch Ana , Ehinger Anna , Nimeus Emma , Hartman Johan , Acs Balazs , Rimm David L.
Published: April 2023

Correlation of TIL scores of overlapped cases between TMA Yale2 and WTS Yale sets